Highlights from our recent pharmacoepidemiology work

This page features selected Analysis Group material, including recent work related to pharmacoepidemiology.

Presence at 2024 ISPE Annual Meeting  

Our health care consultants will present their work through two podium presentations and five research posters at the 2024 ISPE Annual Meeting. We are a proud gold sponsor of this conference. Please see topics below and our 2024 ISPE Presentation Guide for full details. 

Podium Presentations

We will have two podium presentations. Topics include:

Monday, August 26, 1:30 p.m. CEST, Convention Hall I D

• Applying the self-controlled case series to analyze safety endpoints in single-arm, open label extension studies: A case study of Belimumab for the treatment of systemic lupus erythematosus and risk of infection  

Wednesday, August 28, 8:45 a.m. CEST, Room XV 

• Impact of data source diversity on the distribution of key variables in pregnancy cohorts based on the ConcePTION pregnancy algorithm leveraging a random forest imputation model  

Research Posters

We will have five research posters. Topics include:

Poster Session A: Monday, August 26, 8:00 a.m.–6:00 p.m. CEST 

• Poster No. 158: Comparative Effectiveness of ARB and ACEi for Cardiovascular Outcomes and Risk of Angioedema by Ethnicity: an Analysis in the UK Clinical Practice Research Datalink with Emulation of a Reference Trial (ONTARGET)  
• Poster No. 108: Impact of Treatment of COVID-19 with Sotrovimab on Post-Acute COVID-19 Syndrome: An Analysis of National COVID Cohort Collaborative (N3C) Data  
• Poster No. 070: NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis  

Poster Session B: Tuesday, August 27, 8:00 a.m.–6:00 p.m. CEST 

• Poster No. 342: Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine  

Poster Session C: Wednesday, August 28, 8:00 a.m.–1:30 p.m. CEST 

• Poster No. 305: High Misclassification of Glycogen Storage Disease Type 1a in a US Electronic Medical Records Database – Insights from a Physician Note Review  

 

Highlights in Drug Safety Epidemiology

• Analysis Group and Pfizer Present Final Data on COVID-19 Vaccine Safety Surveillance Program of US Veterans Health Administration Patients
• The Acute Effects of Azithromycin Use on Cardiovascular Mortality as Compared with Amoxicillin-Clavulanate in US Veterans
• Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study
• Suicidal Ideation and Attempts in the US Among Stimulant-Treated, Non-Stimulant-Treated, and Untreated Patients with a Diagnosis of Attention-Deficit/Hyperactivity Disorder

Highlights in Regulatory Real-World Evidence (RWE)

• Analysis Group Announces Real-World Evidence Study Supported Blueprint Medicines’ Label Expansion of AYVAKYT® (avapritinib) to Advanced Systemic Mastocytosis in the EU
• Analysis Group’s Real-World Data Study Supports FDA’s Recent ExkivityTM (Mobocertinib) Approval
• Analysis Group Research Sheds Light on Regulatory Real-World Evidence in Successful Oncology Product Approvals

Highlights in Patient-Reported Outcome (PRO) Studies

• A New “Gold Standard”? How Digital Health Technologies Can Be Used to Monitor Patient Progress via PROs
• Patient-Reported Outcomes of Upadacitinib Versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12- And 24-Week Results of A Phase 3 Trial
• Analysis Group Team’s Study Comparing Patient-Reported Outcomes of Psoriasis Therapies Provides Data Critical to Successful Regulatory Submissions
• Analysis Group Coauthors Explore Novel Method for Assessing Real-World Data on Longitudinal Patient-Reported Outcomes
• Analysis Group Researchers Identify Novel Approach for Assessing Real-World Treatment Effectiveness in Patients with IBS-D
• Pair of Digital Health Research Papers Coauthored by Analysis Group Demonstrate Promises of Wearables to Generate Reliable Site-Less Patient-Reported Outcomes in Rheumatoid Arthritis 

Highlights in Artificial Intelligence/Machine Learning

• Profiling Disease and Economic Burden in CRSwNP Using Machine Learning
• Identifying Individuals with Undiagnosed Post-Traumatic Stress Disorder in a Large United States Civilian Population – A Machine Learning Approach
• Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model
• Analysis Group Researchers Identify Neighborhood Characteristics That May Predict Psoriasis in Quebec, Canada
• Analysis Group Researchers Develop a Novel Framework to Help Clinicians Predict the Likelihood of Antibiotic-Resistant Bacteria in Patients with Uncomplicated Urinary Tract Infections 

Compendium of Published Research and Presentations

• Epidemiology, Health Economics, and Outcomes Research: Published Research and Presentations

Click here to learn more about our work. Access our career opportunities here.